- Home
- FMST vs CMMB Comparison
FMST vs CMMB Comparison
Compare FMST & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMST
- CMMB
- Stock Information
- Founded
- FMST 2005
- CMMB 2004
- Country
- FMST Canada
- CMMB Israel
- Employees
- FMST N/A
- CMMB 20
- Industry
- FMST Other Metals and Minerals
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- FMST Basic Materials
- CMMB Health Care
- Exchange
- FMST Nasdaq
- CMMB Nasdaq
- Market Cap
- FMST 15.9M
- CMMB 20.9M
- IPO Year
- FMST N/A
- CMMB N/A
- Fundamental
- Price
- FMST $2.49
- CMMB $1.13
- Analyst Decision
- FMST
- CMMB Strong Buy
- Analyst Count
- FMST 0
- CMMB 3
- Target Price
- FMST N/A
- CMMB $5.67
- AVG Volume (30 Days)
- FMST 7.4K
- CMMB 148.4K
- Earning Date
- FMST 01-01-0001
- CMMB 11-07-2024
- Dividend Yield
- FMST N/A
- CMMB N/A
- EPS Growth
- FMST N/A
- CMMB N/A
- EPS
- FMST N/A
- CMMB N/A
- Revenue
- FMST N/A
- CMMB N/A
- Revenue This Year
- FMST N/A
- CMMB N/A
- Revenue Next Year
- FMST N/A
- CMMB N/A
- P/E Ratio
- FMST N/A
- CMMB N/A
- Revenue Growth
- FMST N/A
- CMMB N/A
- 52 Week Low
- FMST $1.77
- CMMB $0.42
- 52 Week High
- FMST $4.25
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- FMST 28.64
- CMMB 28.21
- Support Level
- FMST $2.47
- CMMB $1.29
- Resistance Level
- FMST $2.95
- CMMB $1.59
- Average True Range (ATR)
- FMST 0.23
- CMMB 0.17
- MACD
- FMST -0.05
- CMMB -0.06
- Stochastic Oscillator
- FMST 12.09
- CMMB 4.41
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Lithium Resource & Technology Ltd is a hard-rock exploration company strategically located to capitalize on the growing EV appetite and is committed to being a supplier of North America's lithium feedstock. As the transition towards decarbonization, the company is focused on the exploration and growth of its five Lithium Lane Projects in Snow Lake Manitoba. It also has the Winston Gold/Silver Property in New Mexico, USA. The company mainly operates in one reportable operating segment being the acquisition and exploration of exploration and evaluation assets.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.